Clinical Trial Update: Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a three-drug regimen of epirubicin, docetaxel, and capecitabine in women with Stage IIIA/IIIB breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)

Snippet

Sponsor: Mayo Clinic | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED